A new class of drugs for a novel biologic target
Pioneering science in the most advanced therapeutic program for this receptor
Certa has a pipeline of candidate drugs that target GPR68 each designed to address different fibrotic indications.
Figure: The development pipeline for key Certa compounds. Next generation compounds have been developed and are in the early stages of pre-clinical development.
Using genetic information to identify patients that will best respond to a specific treatment.
Precision medicine uses diagnostic tests to treat the right patients at the right time based on their genetic make-up and stage of disease.
Certa Therapeutics is seeking to combine our innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, providing potential for a precision therapy.
We have demonstrated that many of the inflammatory and fibrotic molecular pathways dysregulated in animal models of chronic kidney disease are replicated in human disease in early phase trials.
In animals, FT011 (asengeprast) treatment broadly reverses inflammatory and fibrotic pathways back to a non-diseased state.
Fibrosis is a pathological wound healing process which when continues unchecked, leads to considerable tissue remodelling and deposition of connective tissue. The result is interference or complete inhibition and loss of function of the organ affected.
There are no approved drugs which effectively inhibit progression of tissue fibrosis for any chronic systemic disease.
Fibrosis contributes to many serious and life-limiting fibrotic diseases, including the following:
Scleroderma
Scleroderma: a rare and potentially life-threatening autoimmune disorder characterised by inflammation and fibrosis of the skin and other organs.
Chronic Kidney Disease
Chronic kidney disease (CKD) encompasses all degrees of decreased kidney function, from mild or moderate disease to severe and end organ failure.
Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis is one of the many kidney conditions described under the umbrella of glomerulonephritis (inflammation of the kidney), which can lead to chronic kidney disease. FSGS is a condition that results in hardening or thickening of the glomeruli, which act as filters inside the nephrons of the kidney.
Diabetic Nephropathy
Diabetic nephropathy, or diabetic kidney disease (DKD) is a common complication of diabetes, where there is a decline in kidney function and reduced ability to filter out excess proteins from the blood.
Diabetic Retinopathy
Fibrosis is observed in multiple eye diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), where the deposition of scar tissue is irreversible, impacting vision and, in the case of DR, can ultimately lead to blindness.
Disclaimer
All of the candidate drugs described on this site are investigational products which have not received marketing authorization or approval by any regulatory agency, including the US Food and Drug Administration, the European Medicines Agency, or the Australian Therapeutic Goods Administration. The investigational drug products are undergoing clinical studies to evaluate the safety and effectiveness in humans.